Fertility startup Inito wants to use AI-designed antibodies to expand at-home health tests

Summary

Fertility startup Inito has raised $29 million in Series B funding to scale its at-home health diagnostics platform and use AI-designed antibodies to unlock new kinds of at-home tests. When the company launched its first fertility monitor in 2021, its goal was to make quantitative fertility hormone testing possible at home. While standard at-home ovulation tests predict fertile days by tracking estrogen and Luteinizing hormone (LH), they don’t measure the hormone that confirms your ovulation, which is progesterone metabolite PdG. Inito allows women to measure estrogen, LH, progesterone (PdG), and FSH on a single test strip. Inito’s AI models interpret these levels to reveal fertility hormone patterns, track fertile days, and confirm ovulation. Fast forward to today, the startup has become a popular option for women looking to track fertility hormones, analyzing more than 30 million fertility hormone data points since 2021. The startup is now doubling down on its belief that healthcare should start at home, and is working to evolve Inito from a fertility tracker into a broader hormone and at-home health diagnostics platform. Image Credits:Inito Inito is using the new funding to invest in and develop AI-engineered antibodies, which it says will allow for the development of new types of tests and improve the accuracy of existing ones. For context, when you take a test at a lab or a home, antibodies are what bind to the target molecule (such as estrogen or testosterone) to produce a signal. Traditional antibodies are grown inside animals and then screened manually in the lab, which can be a slow and expensive process. Conventional antibodies also lack the sensitivity to make at-home tests for a large number of biomarkers. Techcrunch event San Francisco | October 13-15, 2026 Inito says AI-designed antibodies change the game. Instead of “raising” antibodies in animals, they can be treated almost like software. “We predict how proteins fold in 3D, design synthetic antibodi...